PubMed

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.

Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A.

Diabetes. 2002 May;51(5):1507-14.PMID: 11978649 [PubMed - indexed for MEDLINE]Related articlesFree article

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C.

FASEB J. 2002 Jul;16(9):1027-40.PMID: 12087064 [PubMed - indexed for MEDLINE]Related articlesFree article

Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.

Zingarelli B, Hake PW, Mangeshkar P, O'Connor M, Burroughs TJ, Piraino G, Denenberg A, Wong HR.

Shock. 2007 Nov;28(5):554-63.PMID: 17589386 [PubMed - indexed for MEDLINE]Related articles

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH.

Circulation. 2001 Nov 20;104(21):2588-94.PMID: 11714655 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.

Molavi B, Chen J, Mehta JL.

Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H687-93. Epub 2006 Mar 31.PMID: 16582019 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.

Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM.

Diabetes. 2005 Feb;54(2):554-62.PMID: 15677515 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide.

Gonon AT, Bulhak A, Labruto F, Sjöquist PO, Pernow J.

Basic Res Cardiol. 2007 Jan;102(1):80-9. Epub 2006 Aug 14.PMID: 16900441 [PubMed - indexed for MEDLINE]Related articles

Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion.

Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL.

Cardiovasc Res. 2004 Apr 1;62(1):135-44.PMID: 15023560 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.

Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU.

Diabetes. 2003 Sep;52(9):2331-7.PMID: 12941773 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.

Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, Quon MJ, Karnieli E.

J Biol Chem. 2003 Aug 15;278(33):30614-23. Epub 2003 May 29.PMID: 12777391 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.

Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ.

Mol Pharmacol. 2001 Apr;59(4):765-73.PMID: 11259621 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C.

Br J Pharmacol. 2003 Sep;140(2):366-76. Epub 2003 Aug 11.PMID: 12970094 [PubMed - indexed for MEDLINE]Related articlesFree article

Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing-dependent manner.

Pantos C, Bescond-Jacquet A, Tzeis S, Paizis I, Mourouzis I, Moraitis P, Malliopoulou V, Politi ED, Karageorgiou H, Varonos D, Cokkinos DV.

Basic Res Cardiol. 2005 Mar;100(2):154-60. Epub 2004 Dec 23.PMID: 15616764 [PubMed - indexed for MEDLINE]Related articles

Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method.

Abe M, Takiguchi Y, Ichimaru S, Kaji S, Tsuchiya K, Wada K.

Eur J Pharmacol. 2008 Jul 28;589(1-3):215-9. Epub 2008 May 16.PMID: 18571644 [PubMed - indexed for MEDLINE]Related articles

Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.

Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, Shibasaki M, Shikama H.

Biochem Pharmacol. 2003 Mar 1;65(5):795-805.PMID: 12628477 [PubMed - indexed for MEDLINE]Related articles

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.

Rieusset J, Auwerx J, Vidal H.

Biochem Biophys Res Commun. 1999 Nov;265(1):265-71.PMID: 10548525 [PubMed - indexed for MEDLINE]Related articles

Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats.

Naito Y, Takagi T, Uchiyama K, Handa O, Tomatsuri N, Imamoto E, Kokura S, Ichikawa H, Yoshida N, Yoshikawa T.

Redox Rep. 2002;7(5):294-9.PMID: 12688513 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

Jiang G, Dallas-Yang Q, Biswas S, Li Z, Zhang BB.

Biochem J. 2004 Jan 15;377(Pt 2):339-46.PMID: 14556646 [PubMed - indexed for MEDLINE]Related articlesFree article

Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.

Chai W, Wu Y, Li G, Cao W, Yang Z, Liu Z.

Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E183-9. Epub 2007 Nov 14.PMID: 18003719 [PubMed - indexed for MEDLINE]Related articlesFree article

Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury.

Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Maulik G, Bagchi M, Bagchi D, Maulik N.

Biochim Biophys Acta. 2009 Jan;1792(1):39-48. Epub 2008 Nov 5.PMID: 19027847 [PubMed - indexed for MEDLINE]Related articles